Acurx Pharmaceuticals, Inc. - Common Stock (ACXP)

Competitors to Acurx Pharmaceuticals, Inc. - Common Stock (ACXP)

Melinta Therapeutics, Inc.

Melinta Therapeutics focuses on developing and commercializing antibiotics for serious bacterial infections, which aligns closely with Acurx Pharmaceuticals' mission. Both companies target the significant unmet need for effective antibiotics against multi-drug-resistant bacteria. Melinta has a portfolio of marketed products that provide it with a revenue stream and established relationships with healthcare providers, giving it a competitive advantage over Acurx, which is still advancing its drug candidates through clinical trials.

Nabriva Therapeutics plc

Nabriva Therapeutics concentrates on developing and commercializing novel antibiotics for the treatment of acute bacterial infections, similar to the focus of Acurx Pharmaceuticals. Nabriva has a unique approach with its two marketed products, which offer a strong foundation for continued revenue and growth in a competitive market. While Acurx is still innovating and testing its products, Nabriva's established presence allows it to potentially leverage existing networks for market penetration, placing it in a leading position in direct competition.

Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals specializes in developing and commercializing innovative therapies for patients with serious infections. Similar to Acurx Pharmaceuticals, Paratek’s primary focus is on addressing antibiotic resistance, utilizing a unique mechanism of action that sets its products apart. The two companies compete in the same therapeutic area, particularly in the development of treatments for bacterial infections. Paratek has an established product in the market, while Acurx is still in various stages of development, giving Paratek a competitive edge in terms of market presence and revenue generation.

Synthetic Biologics, Inc.

Synthetic Biologics develops therapies for the treatment of diseases related to microbiome dysbiosis. While their focus slightly diverges from Acurx Pharmaceuticals’ core specialization in antibiotic development, there is overlap in addressing antibiotic-resistant infections. The competition comes into play primarily in the broader spectrum of infectious diseases. Synthetic Biologics utilizes a different therapeutic approach, but their advances in microbiome-targeted treatments may distract from traditional antibiotic avenues, offering them a niche advantage in the evolving landscape. However, Acurx's direct focus on antibiotic treatments gives it a more specific and potentially impactful market presence.

Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals is engaged in developing a new class of antibiotics, particularly targeting resistant Gram-negative bacteria, which is also a focus area for Acurx Pharmaceuticals. Both companies are positioned within the same market space; however, Tetraphase has made strides in bringing products to market and thereby achieving recognition and a foothold in the competitive landscape, whereas Acurx is in the earlier phases of development with its antibiotic candidates. This existing market presence gives Tetraphase a notable advantage in terms of sales and partnerships.